Vista Pharmaceuticals Limited (BOM:524711)
India · Delayed Price · Currency is INR 7.28
0.00 (0.00%)
At close: Feb 12, 2026
Vista Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 87.66 | 100.75 | 102.88 | 10.04 | 3.95 | 12.66 |
Other Revenue | -0 | - | - | - | -0 | - |
| 87.66 | 100.75 | 102.88 | 10.04 | 3.95 | 12.66 | |
Revenue Growth (YoY) | -3.95% | -2.07% | 924.99% | 154.42% | -68.85% | -94.44% |
Cost of Revenue | 83.4 | 85.34 | 92.86 | 28.61 | 3.9 | 8.47 |
Gross Profit | 4.27 | 15.41 | 10.02 | -18.57 | 0.05 | 4.2 |
Selling, General & Admin | 23.79 | 21.97 | 20.17 | 5.34 | 7.17 | 12.11 |
Other Operating Expenses | 48.9 | 32.37 | 21.71 | 14.93 | 4.99 | 9.39 |
Operating Expenses | 80.15 | 61.72 | 49.07 | 26.44 | 18.32 | 28.77 |
Operating Income | -75.88 | -46.31 | -39.05 | -45.01 | -18.27 | -24.57 |
Interest Expense | -7.6 | -9.24 | -12.34 | -13.1 | -8.98 | -15.45 |
Interest & Investment Income | 1.75 | 1.75 | 1.45 | 1.29 | 1.66 | 1 |
Currency Exchange Gain (Loss) | -0.41 | -0.41 | -0.69 | -1.63 | -0.57 | - |
Other Non Operating Income (Expenses) | 2.46 | 1.32 | 1.43 | -0.31 | -0.02 | 0.91 |
EBT Excluding Unusual Items | -79.69 | -52.9 | -49.21 | -58.76 | -26.18 | -38.11 |
Other Unusual Items | - | - | -2.57 | - | - | - |
Pretax Income | -79.69 | -52.9 | -51.77 | -58.76 | -26.18 | -38.11 |
Income Tax Expense | -12.72 | -6.41 | -6.65 | -2.14 | -17.29 | -18.03 |
Net Income | -66.97 | -46.49 | -45.12 | -56.62 | -8.89 | -20.09 |
Net Income to Common | -66.97 | -46.49 | -45.12 | -56.62 | -8.89 | -20.09 |
Shares Outstanding (Basic) | 59 | 59 | 44 | 37 | 37 | 35 |
Shares Outstanding (Diluted) | 59 | 59 | 44 | 37 | 37 | 35 |
Shares Change (YoY) | 11.64% | 34.66% | 18.55% | 0.11% | 6.18% | 14.11% |
EPS (Basic) | -1.14 | -0.79 | -1.03 | -1.54 | -0.24 | -0.58 |
EPS (Diluted) | -1.14 | -0.79 | -1.03 | -1.54 | -0.24 | -0.58 |
Free Cash Flow | -64.31 | -74.25 | -57.04 | -29.82 | -10.07 | -70.46 |
Free Cash Flow Per Share | -1.10 | -1.26 | -1.31 | -0.81 | -0.27 | -2.03 |
Gross Margin | 4.87% | 15.29% | 9.74% | -185.00% | 1.22% | 33.14% |
Operating Margin | -86.56% | -45.97% | -37.96% | -448.47% | -463.07% | -194.04% |
Profit Margin | -76.39% | -46.14% | -43.86% | -564.11% | -225.25% | -158.62% |
Free Cash Flow Margin | -73.36% | -73.70% | -55.44% | -297.07% | -255.34% | -556.35% |
EBITDA | -68.42 | -38.93 | -31.86 | -38.84 | -12.11 | -17.3 |
EBITDA Margin | -78.05% | -38.64% | -30.96% | - | - | -136.58% |
D&A For EBITDA | 7.46 | 7.38 | 7.2 | 6.18 | 6.16 | 7.28 |
EBIT | -75.88 | -46.31 | -39.05 | -45.01 | -18.27 | -24.57 |
EBIT Margin | -86.56% | -45.97% | -37.96% | - | - | -194.04% |
Revenue as Reported | 93.21 | 105.15 | 106.21 | 14.03 | 5.6 | 14.61 |
Advertising Expenses | - | 0.79 | 1.14 | 0.1 | 0.66 | 0.08 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.